DBV Technologies (NASDAQ: DBVT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The firm presently has a $ 1.50 target price on the stock. Zacks Investment Research’s target price indicates a potential upside of 9.49% from the company’s current price.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

DBVT has been the topic of several other research reports. Societe Generale downgraded DBV Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, January 19th. HC Wainwright reissued a “buy” rating and set a $ 10.00 target price on shares of DBV Technologies in a research note on Tuesday. Finally, StockNews.com assumed coverage on DBV Technologies in a research report on Thursday. They set a “hold” rating for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $ 5.50.

DBVT opened at $ 1.37 on Thursday. The firm has a market cap of $ 150.96 million, a price-to-earnings ratio of -1.76 and a beta of 2.16. DBV Technologies has a 12 month low of $ 1.20 and a 12 month high of $ 6.58. The stock has a fifty day moving average price of $ 1.46 and a 200-day moving average price of $ 2.03.

DBV Technologies (NASDAQ: DBVT – Get Rating) last announced its quarterly earnings data on Thursday, March 3rd. The company reported ($ 0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($ 0.32) by $ 0.19. The firm had revenue of $ 2.93 million during the quarter, compared to analyst estimates of $ 3.97 million. On average, research analysts forecast that DBV Technologies will post -0.69 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. OLD Mission Capital LLC increased its holdings in shares of DBV Technologies by 647.4% during the 3rd quarter. OLD Mission Capital LLC now owns 137,880 shares of the company’s stock worth $ 239,000 after buying an additional 119,432 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in DBV Technologies in the 4th quarter valued at $ 32,000. BlackRock Inc. increased its holdings in DBV Technologies by 2,539.5% in the 4th quarter. BlackRock Inc. now owns 589,929 shares of the company’s stock valued at $ 944,000 after purchasing an additional 567,579 shares in the last quarter. Jane Street Group LLC purchased a new position in DBV Technologies in the 3rd quarter valued at about $ 547,000. Finally, Credit Suisse AG purchased a new position in DBV Technologies in the 4th quarter valued at about $ 123,000. 19.33% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies (Get Rating)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.

Featured Stories

Get a free copy of the Zacks research report on DBV Technologies (DBVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com



Receive News & Ratings for DBV Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DBV Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

.

By admin

Leave a Reply

Your email address will not be published.